{"entity":{"type":"insider","cik":"0001277503","url":"/insider/0001277503","json_url":"/insider/0001277503.json","name":"KANEKO YASUNORI","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":11,"first":"2011-02-18","last":"2025-02-27","span_basis":"filed_date"},"name_variants":[{"name":"KANEKO YASUNORI","source":"filing","n_filings":11,"first_seen":"2011-02-18","last_seen":"2025-02-27"}],"transactions":[{"id":4278744,"accession":"0001724521-25-000046","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001724521-25-000046","line_url":"/filing/0001724521-25-000046#line-1","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":"0001277503","owner_name":"KANEKO YASUNORI","owner_display_name":"KANEKO YASUNORI","owner_url":"/insider/0001277503","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":10.06,"price_display":"10.06","price_state":"stated","total_value":201200.0,"total_display":"201,200.00","total_whole":"201,200","shares_owned_after":28400.0,"shares_owned_after_display":"28,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-27","filed_date":"2025-02-27","scope":"insider"},{"id":4891129,"accession":"0001179110-21-004605","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-21-004605","line_url":"/filing/0001179110-21-004605#line-1","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":"0001277503","owner_name":"KANEKO YASUNORI","owner_display_name":"KANEKO YASUNORI","owner_url":"/insider/0001277503","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4133.0,"shares_display":"4,133","price_per_share":31.37,"price_display":"31.37","price_state":"stated","total_value":129652.21,"total_display":"129,652.21","total_whole":"129,652","shares_owned_after":7133.0,"shares_owned_after_display":"7,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-23","filed_date":"2021-04-26","scope":"insider"},{"id":6708054,"accession":"0001209191-18-055698","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-18-055698","line_url":"/filing/0001209191-18-055698#line-5","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"SI-BONE, Inc.","issuer_ticker":"SIBN","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"Skyline Venture Partners V LP; KANEKO YASUNORI; Skyline Venture Management V, LLC; Freund John Gordon","owner_display_name":"Skyline Venture Partners V LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":325000.0,"shares_display":"325,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4875000.0,"total_display":"4,875,000.00","total_whole":"4,875,000","shares_owned_after":4419985.0,"shares_owned_after_display":"4,419,985","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-19","filed_date":"2018-10-19","scope":"insider"},{"id":8812120,"accession":"0001209191-15-042578","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-15-042578","line_url":"/filing/0001209191-15-042578#line-4","is_derivative":false,"issuer_cik":"0001267565","issuer_name":"COLLEGIUM PHARMACEUTICAL, INC","issuer_ticker":"COLL","issuer_name_source":null,"issuer_url":"/issuer/0001267565","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners V LP; Skyline Venture Management V, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":1800000.0,"total_display":"1,800,000.00","total_whole":"1,800,000","shares_owned_after":2949916.0,"shares_owned_after_display":"2,949,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-05-12","filed_date":"2015-05-13","scope":"insider"},{"id":8533674,"accession":"0001209191-15-018139","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-018139","line_url":"/filing/0001209191-15-018139#line-1","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"Freund John Gordon; Skyline Venture Management V, LLC; KANEKO YASUNORI; Skyline Venture Partners V LP","owner_display_name":"Freund John Gordon","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37532.0,"shares_display":"37,532","price_per_share":26.02,"price_display":"26.02","price_state":"stated","total_value":976582.64,"total_display":"976,582.64","total_whole":"976,583","shares_owned_after":1719671.0,"shares_owned_after_display":"1,719,671","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-02-20","filed_date":"2015-02-24","scope":"insider"},{"id":6692498,"accession":"0001104659-14-074955","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-14-074955","line_url":"/filing/0001104659-14-074955#line-3","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"PROTEON THERAPEUTICS INC","issuer_ticker":"PRTO","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Freund John Gordon; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56038.0,"shares_display":"56,038","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":560380.0,"total_display":"560,380.00","total_whole":"560,380","shares_owned_after":1432930.0,"shares_owned_after_display":"1,432,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-27","filed_date":"2014-10-29","scope":"insider"},{"id":6692496,"accession":"0001104659-14-074955","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-14-074955","line_url":"/filing/0001104659-14-074955#line-2","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"PROTEON THERAPEUTICS INC","issuer_ticker":"PRTO","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Freund John Gordon; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-27","filed_date":"2014-10-29","scope":"insider"},{"id":6926954,"accession":"0001104659-14-012353","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-14-012353","line_url":"/filing/0001104659-14-012353#line-4","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"Skyline Venture Management IV, LLC; Skyline Venture Partners Qualified Purchaser Fund IV L P; KANEKO YASUNORI","owner_display_name":"Skyline Venture Management IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":2100000.0,"total_display":"2,100,000.00","total_whole":"2,100,000","shares_owned_after":1208920.0,"shares_owned_after_display":"1,208,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-20","filed_date":"2014-02-21","scope":"insider"},{"id":6600047,"accession":"0001104659-14-006845","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-14-006845","line_url":"/filing/0001104659-14-006845#line-4","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"Skyline Venture Management V, LLC; Freund John Gordon; Skyline Venture Partners V LP; KANEKO YASUNORI","owner_display_name":"Skyline Venture Management V, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":1734751.0,"shares_owned_after_display":"1,734,751","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-04","filed_date":"2014-02-05","scope":"insider"},{"id":4238552,"accession":"0001181431-13-019221","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-13-019221","line_url":"/filing/0001181431-13-019221#line-5","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"TETRAPHASE PHARMACEUTICALS INC","issuer_ticker":"TTPH","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":681012.0,"shares_display":"681,012","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":4767084.0,"total_display":"4,767,084.00","total_whole":"4,767,084","shares_owned_after":2190145.0,"shares_owned_after_display":"2,190,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-25","filed_date":"2013-03-27","scope":"insider"},{"id":3000548,"accession":"0001104659-12-041088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-12-041088","line_url":"/filing/0001104659-12-041088#line-1","is_derivative":false,"issuer_cik":"0001190418","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001190418","owner_cik":null,"owner_name":"Freund John Gordon; KANEKO YASUNORI; HOFFMAN STEPHEN J; Skyline Venture Partners Qualified Purchaser Fund IV L P; Skyline Venture Management IV, LLC","owner_display_name":"Freund John Gordon","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":284698.0,"shares_display":"284,698","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":967973.2,"total_display":"967,973.20","total_whole":"967,973","shares_owned_after":4161933.0,"shares_owned_after_display":"4,161,933","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-29","filed_date":"2012-05-31","scope":"insider"},{"id":9069653,"accession":"0001181431-11-011591","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-11-011591","line_url":"/filing/0001181431-11-011591#line-6","is_derivative":false,"issuer_cik":"0001190418","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001190418","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; HOFFMAN STEPHEN J; Skyline Venture Management IV, LLC; Freund John Gordon","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1235943.0,"shares_display":"1,235,943","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":6179715.0,"total_display":"6,179,715.00","total_whole":"6,179,715","shares_owned_after":3877235.0,"shares_owned_after_display":"3,877,235","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":2,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":2},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001724521","name":"Arcus Biosciences, Inc.","url":"/issuer/0001724521","role":"Director","n_filings":2,"first_seen":"2021-04-26","last_seen":"2025-02-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001459839","name":"SI-BONE, Inc.","url":"/issuer/0001459839","role":"Ten percent owner","n_filings":1,"first_seen":"2018-10-19","last_seen":"2018-10-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001267565","name":"COLLEGIUM PHARMACEUTICAL, INC","url":"/issuer/0001267565","role":"Ten percent owner","n_filings":1,"first_seen":"2015-05-13","last_seen":"2015-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001399529","name":"Dicerna Pharmaceuticals Inc","url":"/issuer/0001399529","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2014-02-05","last_seen":"2015-02-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001359931","name":"PROTEON THERAPEUTICS INC","url":"/issuer/0001359931","role":"Ten percent owner","n_filings":1,"first_seen":"2014-10-29","last_seen":"2014-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Ten percent owner","n_filings":1,"first_seen":"2014-02-21","last_seen":"2014-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001373707","name":"TETRAPHASE PHARMACEUTICALS INC","url":"/issuer/0001373707","role":"Ten percent owner","n_filings":1,"first_seen":"2013-03-27","last_seen":"2013-03-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Ten percent owner","n_filings":2,"first_seen":"2011-02-18","last_seen":"2012-05-31"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001277503","retrieved_at":"2026-08-27T06:11:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}